Shire plc (LSE: SHP, NASDAQ: SHPG) announces that, following the appointment of Mark Enyedy as Head of Corporate Development on May 1, 2014, Mr Enyedy, a Person Discharging Managerial Responsibility, was awarded a deferred share award over 1,452 American Depositary Shares (“ADSs”) (the “Award”). The Award was granted on July 28, 2014. One ADS is equal to three Shire ordinary shares of 5 pence each.
The Award will normally vest, subject to continued employment, in two tranches; 50% on May 1, 2016 and 50% on May 1, 2017. No consideration was paid for the grant of the Award.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
Deputy Company Secretary
For further information please contact:
+1 781 482 0945
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
Click here for the PDF version of this press release.